Progress of molecular imaging in multiple myeloma
10.3760/cma.j.cn321828-20200511-00186
- VernacularTitle:多发性骨髓瘤的分子影像学研究进展
- Author:
Cuicui LI
1
;
Rongfu WANG
;
Lei KANG
Author Information
1. 北京大学第一医院核医学科，北京 100034
- Keywords:
Multiple myeloma;
Molecular imaging;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2022;42(1):44-47
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is a malignant tumor of the blood system that is more common in the elderly with abnormal proliferation of bone marrow plasma cells. The current diagnostic methods mainly rely on the detection of M protein and invasive bone marrow aspiration biopsy. The sensitivity and specificity of conventional imaging tests are low. Molecular imaging technology provides new options and methods for the noninvasive diagnosis of MM. Whole-body MRI (WB-MRI) has good soft tissue contrast and spatial resolution, which can show bone marrow infiltration and vascular conditions. Metabolic imaging such as 18F-FDG, acetate, choline, and methionine are highly sensitive. ImmunoPET imaging screens specific targets for targeted therapy or immunotherapy and evaluates the efficacy. This article reviews the progress of molecular imaging in MM, especially immunoPET imaging.
